Tumor relapse in patients with ER+ breast cancer is thought to emerge either from expansion of preexistent drug-resistant clones without any intermediate dormancy (16, 22, 23) or by de novo mechanisms appearing under therapeutic pressure during dormancy (1, 2, 13, 17). The gene discussed is ESR1; the disease is breast cancer.